Mettler-Toledo International Inc (MTD)
Mettler-Toledo International Inc. manufactures and supplies precision instruments and services in the Americas, Europe, Asia, and internationally. It operates through five segments: U.S. Operations, Swiss Operations, Western European Operations, Chinese Operations, and Other Operations. The company offers laboratory instruments, such as laboratory balances, liquid pipetting solutions, real-time analytics, titrators, pH meters, process analytics sensors and analyzer technologies, density and refractometry instruments, and thermal analysis systems; and other analytical instruments, including UV/VIS spectrophotometers, moisture analyzers, and cell counters, as well as LabX, a laboratory software platform to manage and analyze data generated by its instruments and automate workflows. It also provides industrial instruments comprising industrial weighing instruments and related terminals, automatic dimensional measurement and data capture solutions, vehicle scale systems, industrial software, metal detectors, x-ray systems, checkweighers, and camera-based imaging equipment. In addition, the company offers retail weighing solutions consisting of weighing and software solutions, AI-driven image recognition solutions for fresh goods, and automated packaging and labeling solutions for the meat backroom. The company serves pharmaceutical and biotech companies, independent research organizations, and testing labs; food manufacturers and retailers; chemical, specialty chemicals, and cosmetics companies; transportation and logistics, metals, and electronics industries; and academic community through its direct sales force and indirect distribution channels. Mettler-Toledo International Inc. was incorporated in 1991 and is headquartered in Greifensee, Switzerland.
- Symbol
- MTD
- Exchange
- NYSE
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Market cap
- $32.23B
- 52 week range
- 1023.05 - 1554.83
Valuation
- Share price
- $1486.19 (close of 2026-10-02)
- P/E (TTM)
- 33.42x
- Price to free cash flow
- 37.30x
- Enterprise value
- $34.29B
Price performance
| Period | Change |
|---|---|
| 1 day | +0.34% |
| 5 days | -1.68% |
| 1 month | +8.66% |
| 3 months | +13.59% |
| 6 months | +17.96% |
| Year to date | +6.60% |
| 1 year | +14.27% |
| 3 years | +36.68% |
| 5 years | +6.93% |
| 10 years | +254.00% |
| All time | +9887.84% |
Members of Congress who disclosed MTD trades
Julia Letlow · Robert Bresnahan · Julie Johnson
Super investors holding MTD
Ken Griffin (Citadel) · Ray Dalio (Bridgewater Associates) · Wallace Weitz (Weitz Investment Management)
Profitability and growth
- Return on equity
- -3677.41%
- Return on assets
- 23.41%
- Gross margin
- 59.37%
- Net margin
- 21.59%
- EBITDA margin
- 29.02%
- Revenue growth
- 3.98%
- Net income growth
- 0.70%
- Free cash flow growth
- -1.83%
Cash flow and balance sheet
- Free cash flow yield (TTM)
- 2.68%
- Current ratio
- 1.12x
- Net debt to EBITDA
- 1.59x
Latest reported year
- Period end
- 2025-12-31
- Fiscal year
- 2025
- Revenue
- $4.03B
- Gross profit
- $2.39B
- EBITDA
- $1.17B
- Net income
- $869.19M
- Earnings per share
- $42.17
- Research and development
- $199.37M
- Interest expense
- $68.52M
- Shares outstanding
- 20.61M
Income statement by year
| Period end | Revenue | Gross profit | Net income | EPS |
|---|---|---|---|---|
| 2025-12-31 | $4.03B | $2.39B | $869.19M | $42.17 |
| 2024-12-31 | $3.87B | $2.33B | $863.14M | $40.67 |
| 2023-12-31 | $3.79B | $2.24B | $788.78M | $36.10 |
| 2022-12-31 | $3.92B | $2.31B | $872.50M | $38.79 |
| 2021-12-31 | $3.72B | $2.17B | $768.99M | $33.25 |
| 2020-12-31 | $3.09B | $1.80B | $602.74M | $25.24 |
| 2019-12-31 | $3.01B | $1.74B | $561.11M | $22.84 |
| 2018-12-31 | $2.94B | $1.68B | $512.61M | $20.33 |
| 2017-12-31 | $2.73B | $1.58B | $375.97M | $14.62 |
| 2016-12-31 | $2.51B | $1.44B | $384.37M | $14.49 |
Margins and returns by year
| Period end | Gross margin | Net margin | Return on equity |
|---|---|---|---|
| 2025-12-31 | 59.37% | 21.59% | -3677.41% |
| 2024-12-31 | 60.06% | 22.29% | -680.23% |
| 2023-12-31 | 59.16% | 20.82% | -526.07% |
| 2022-12-31 | 58.88% | 22.26% | 3519.15% |
| 2021-12-31 | 58.41% | 20.68% | 448.59% |
| 2020-12-31 | 58.38% | 19.54% | 213.23% |
| 2019-12-31 | 57.87% | 18.65% | 133.35% |
| 2018-12-31 | 57.38% | 17.46% | 86.87% |
| 2017-12-31 | 57.82% | 13.80% | 68.70% |
| 2016-12-31 | 57.32% | 15.32% | 88.37% |
Cash and debt by year
| Period end | Cash | Debt |
|---|---|---|
| 2025-12-31 | $66.89M | $2.09B |
| 2024-12-31 | $59.36M | $1.83B |
| 2023-12-31 | $69.81M | $1.89B |
| 2022-12-31 | $95.97M | $1.91B |
| 2021-12-31 | $98.56M | $1.58B |
| 2020-12-31 | $94.25M | $1.28B |
| 2019-12-31 | $207.78M | $1.24B |
| 2018-12-31 | $178.11M | $985.02M |
| 2017-12-31 | $148.69M | $960.17M |
| 2016-12-31 | $158.67M | $875.06M |
Free cash flow by year
| Period end | Free cash flow | Stock-based compensation |
|---|---|---|
| 2025-12-31 | $848.65M | $22.51M |
| 2024-12-31 | $864.45M | $19.98M |
| 2023-12-31 | $860.55M | $17.93M |
| 2022-12-31 | $737.83M | $19.66M |
| 2021-12-31 | $801.25M | $19.59M |
| 2020-12-31 | $632.21M | $18.69M |
| 2019-12-31 | $506.11M | $18.29M |
| 2018-12-31 | $422.28M | $17.58M |
| 2017-12-31 | $388.90M | $16.58M |
| 2016-12-31 | $336.80M | $15.31M |
Investor relations
Next earnings report
- Next confirmed report
- 2026-11-05
- Consensus EPS estimate
- $12.11
Past earnings dates
| Reported | Fiscal period | EPS estimate |
|---|---|---|
| 2026-07-30 | Jun/2026 | $10.78 |
| 2026-05-07 | Mar/2026 | $8.70 |
| 2026-02-05 | Dec/2025 | $12.76 |
| 2025-11-06 | Sep/2025 | $10.62 |
| 2025-07-31 | Jun/2025 | $9.58 |
| 2025-07-30 | - | - |
| 2025-05-07 | - | - |
| 2025-05-01 | Mar/2025 | $7.90 |
Filings and sources
- Company website
- mt.com
- SEC filings
- 10-K, 10-Q and 8-K on EDGAR
- Earnings calendar
- All upcoming reports
Similar companies
Quest Diagnostics Inc (DGX) · Illumina, Inc. (ILMN) · Labcorp Holdings Inc. (LH) · IDEXX Laboratories Inc (IDXX) · Medpace Holdings, Inc. (MEDP) · Waters Corp (WAT) · Revvity, Inc. (RVTY) · IQVIA Holdings Inc. (IQV)
Understanding these figures
Price-to-earnings ratio · Discounted cash flow · Free cash flow · Earnings per share · Return on equity · Gross margin vs net margin · Reading a balance sheet · Debt and leverage · Dividend yield · Insider transactions and Form 4 · How to read a stock chart
Explore
Company directory · S&P 500 heatmap · Earnings calendar · Super investor holdings · Congress trades